



General Assembly

Substitute Bill No. 1151

January Session, 2003

***AN ACT CONCERNING COLLABORATIVE PRACTICE BETWEEN
PHYSICIANS AND PHARMACISTS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 20-631 of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective October 1, 2003*):

3 (a) (1) One or more pharmacists licensed under this chapter who are
4 determined eligible in accordance with subsection (c) of this section,
5 and employed by a hospital may enter into a written protocol-based
6 collaborative drug therapy management agreement with one or more
7 physicians licensed under chapter 370 to manage the drug therapy of
8 individual patients receiving inpatient services in a hospital licensed
9 under chapter 368v, in accordance with subsections (b) to (d),
10 inclusive, of this section and subject to the approval of the hospital.
11 Each patient's collaborative drug therapy management shall be
12 governed by a written protocol specific to that patient established by
13 the treating physician in consultation with the pharmacist.

14 (2) One or more pharmacists licensed under this chapter who are
15 determined eligible in accordance with subsection (c) of this section
16 and employed by or under contract with a nursing home facility, as
17 defined in section 19a-521, may enter into a written protocol-based
18 collaborative drug therapy management agreement with one or more
19 physicians licensed under chapter 370 to manage the drug therapy of

20 individual patients receiving services in a nursing home facility, in
21 accordance with subsections (b) to (d), inclusive, of this section and
22 subject to the approval of the nursing home facility. Each patient's
23 collaborative drug therapy management shall be governed by a
24 written protocol specific to that patient established by the treating
25 physician in consultation with the pharmacist.

26 (b) A collaborative drug therapy management agreement may
27 authorize a pharmacist to implement, modify or discontinue a drug
28 therapy that has been prescribed for a patient, order associated
29 laboratory tests and administer drugs, all in accordance with a patient-
30 specific written protocol. In instances where drug therapy is
31 discontinued, the pharmacist shall notify the treating physician of such
32 discontinuance no later than twenty-four hours from the time of such
33 discontinuance. Each protocol developed, pursuant to the collaborative
34 drug therapy management agreement, shall contain detailed direction
35 concerning the actions that the pharmacist may perform for that
36 patient. The protocol shall include, but need not be limited to, (1) the
37 specific drug or drugs to be managed by the pharmacist, (2) the terms
38 and conditions under which drug therapy may be implemented,
39 modified or discontinued, (3) the conditions and events upon which
40 the pharmacist is required to notify the physician, and (4) the
41 laboratory tests that may be ordered. All activities performed by the
42 pharmacist in conjunction with the protocol shall be documented in
43 the patient's medical record. The pharmacist shall report at least every
44 thirty days to the physician regarding the patient's drug therapy
45 management. The collaborative drug therapy management agreement
46 and protocols shall be available for inspection by the Departments of
47 Public Health and Consumer Protection. A copy of the protocol shall
48 be filed in the patient's medical record.

49 (c) A pharmacist shall be responsible for demonstrating, in
50 accordance with this subsection, the competence necessary for
51 participation in each drug therapy management agreement into which
52 such pharmacist enters. The pharmacist's competency shall be
53 determined by the hospital or nursing home facility for which the

54 pharmacist is employed. A copy of the criteria upon which the hospital
55 or nursing home facility determines competency shall be filed with the
56 Commission of Pharmacy.

57 (d) The Commissioner of Public Health, in consultation with the
58 Commissioner of Consumer Protection, may adopt regulations, in
59 accordance with chapter 54, concerning the minimum content of the
60 collaborative drug therapy management agreement and the written
61 protocol and as otherwise necessary to carry out the purpose of this
62 section.

| | |
|--|------------------------|
| This act shall take effect as follows: | |
| Section 1 | <i>October 1, 2003</i> |

PH *Joint Favorable Subst.*

HS *Joint Favorable*